Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Dermatol Ther. 2019 Nov;32(6):e13107. doi: 10.1111/dth.13107. Epub 2019 Oct 21.

Affiliations

¹ Skin Cancer Unit, Department of Dermatology, University Hospital of Trieste, Trieste, Italy.
² Skin Cancer Unit, Department of Medical Oncology, Maggiore Hospital of Trieste, Trieste, Italy.
³ Skin Cancer Unit, Department of Plastic Surgery, University Hospital of Trieste, Trieste, Italy.
⁴ Department of Medical Oncology-Preventive Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.

PMID: 31595596
DOI: 10.1111/dth.13107

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / pathology
Drug Resistance, Neoplasm
Humans
Male
Neoplasm Staging
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
pembrolizumab